| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.
|
N Engl J Med
|
2002
|
36.55
|
|
2
|
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
|
N Engl J Med
|
2009
|
14.31
|
|
3
|
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
|
N Engl J Med
|
2008
|
9.33
|
|
4
|
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
|
N Engl J Med
|
2013
|
8.49
|
|
5
|
Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.
|
N Engl J Med
|
2014
|
7.73
|
|
6
|
Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B.
|
N Engl J Med
|
2008
|
7.22
|
|
7
|
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
|
N Engl J Med
|
2014
|
6.31
|
|
8
|
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
|
Gastroenterology
|
2010
|
6.14
|
|
9
|
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.
|
N Engl J Med
|
2003
|
5.97
|
|
10
|
Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.
|
N Engl J Med
|
2007
|
5.13
|
|
11
|
Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values.
|
Hepatology
|
2003
|
4.69
|
|
12
|
Surveillance for hepatocellular carcinoma in patients with cirrhosis improves outcome.
|
Am J Med
|
2008
|
4.07
|
|
13
|
Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C.
|
Hepatology
|
2009
|
3.50
|
|
14
|
Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.
|
Control Clin Trials
|
2004
|
3.46
|
|
15
|
Outcome of sustained virological responders with histologically advanced chronic hepatitis C.
|
Hepatology
|
2010
|
3.35
|
|
16
|
Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection.
|
N Engl J Med
|
2015
|
3.13
|
|
17
|
Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.
|
J Hepatol
|
2005
|
3.10
|
|
18
|
Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial.
|
Clin Gastroenterol Hepatol
|
2010
|
2.96
|
|
19
|
The impact of fat distribution on the severity of nonalcoholic fatty liver disease and metabolic syndrome.
|
Hepatology
|
2007
|
2.94
|
|
20
|
A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis.
|
Clin Gastroenterol Hepatol
|
2004
|
2.84
|
|
21
|
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
|
Gastroenterology
|
2010
|
2.81
|
|
22
|
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.
|
Hepatology
|
2008
|
2.44
|
|
23
|
A survey of liver transplantation from living adult donors in the United States.
|
N Engl J Med
|
2003
|
2.37
|
|
24
|
Definition of rapid virologic response with a highly sensitive real-time PCR-based HCV RNA assay in peginterferon alfa-2a plus ribavirin response-guided therapy.
|
J Hepatol
|
2010
|
2.35
|
|
25
|
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
|
Gastroenterology
|
2004
|
2.28
|
|
26
|
Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin.
|
Hepatology
|
2010
|
2.20
|
|
27
|
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C.
|
Hepatology
|
2007
|
2.16
|
|
28
|
Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment.
|
Clin Gastroenterol Hepatol
|
2006
|
2.12
|
|
29
|
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
|
Hepatology
|
2006
|
2.06
|
|
30
|
Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate.
|
Gastroenterology
|
2010
|
2.06
|
|
31
|
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.
|
Hepatology
|
2009
|
2.02
|
|
32
|
Phase 1b study of pegylated interferon lambda 1 with or without ribavirin in patients with chronic genotype 1 hepatitis C virus infection.
|
Hepatology
|
2010
|
2.02
|
|
33
|
Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C.
|
Hepatology
|
2006
|
1.98
|
|
34
|
High sustained virologic response rates in rapid virologic response patients in the large real-world PROPHESYS cohort confirm results from randomized clinical trials.
|
Hepatology
|
2012
|
1.76
|
|
35
|
Effect of hyponatraemia on outcomes following orthotopic liver transplantation.
|
Liver Int
|
2009
|
1.76
|
|
36
|
Hepatic steatosis in hepatitis C: comparison of diabetic and nondiabetic patients in the hepatitis C antiviral long-term treatment against cirrhosis trial.
|
Clin Gastroenterol Hepatol
|
2007
|
1.71
|
|
37
|
A sustained virologic response is durable in patients with chronic hepatitis C treated with peginterferon alfa-2a and ribavirin.
|
Gastroenterology
|
2010
|
1.70
|
|
38
|
A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.
|
Arch Intern Med
|
2006
|
1.67
|
|
39
|
Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis.
|
Hepatology
|
2010
|
1.66
|
|
40
|
Retreatment with telaprevir combination therapy in hepatitis C patients with well-characterized prior treatment response.
|
Hepatology
|
2011
|
1.62
|
|
41
|
Viral and metabolic factors influencing alanine aminotransferase activity in patients with chronic hepatitis C.
|
J Hepatol
|
2006
|
1.60
|
|
42
|
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.
|
J Hepatol
|
2011
|
1.59
|
|
43
|
Outcomes in hepatitis C virus-infected recipients of living donor vs. deceased donor liver transplantation.
|
Liver Transpl
|
2007
|
1.58
|
|
44
|
Rapid virological response is the most important predictor of sustained virological response across genotypes in patients with chronic hepatitis C virus infection.
|
J Hepatol
|
2010
|
1.51
|
|
45
|
Virologic response rates of weight-based taribavirin versus ribavirin in treatment-naive patients with genotype 1 chronic hepatitis C.
|
Hepatology
|
2010
|
1.47
|
|
46
|
Sustained hepatitis B e antigen seroconversion in patients with chronic hepatitis B after adefovir dipivoxil treatment: analysis of precore and basal core promoter mutants.
|
Clin Infect Dis
|
2008
|
1.47
|
|
47
|
Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C.
|
Nat Rev Gastroenterol Hepatol
|
2011
|
1.46
|
|
48
|
DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4.
|
Liver Int
|
2014
|
1.42
|
|
49
|
Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome.
|
Am J Gastroenterol
|
2003
|
1.42
|
|
50
|
Oral IDN-6556, an antiapoptotic caspase inhibitor, may lower aminotransferase activity in patients with chronic hepatitis C.
|
Hepatology
|
2007
|
1.38
|
|
51
|
Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C.
|
Gastroenterology
|
2006
|
1.38
|
|
52
|
A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans.
|
Clin Gastroenterol Hepatol
|
2004
|
1.33
|
|
53
|
Adult living donor versus deceased donor liver transplantation: a 6-year single center experience.
|
Am J Transplant
|
2005
|
1.31
|
|
54
|
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
|
Hepatology
|
2004
|
1.30
|
|
55
|
Racial differences in hepatitis C treatment eligibility.
|
Hepatology
|
2011
|
1.28
|
|
56
|
A randomized controlled trial of pretransplant antiviral therapy to prevent recurrence of hepatitis C after liver transplantation.
|
Hepatology
|
2013
|
1.21
|
|
57
|
HCV RNA detection by TMA during the hepatitis C antiviral long-term treatment against cirrhosis (Halt-C) trial.
|
Hepatology
|
2006
|
1.13
|
|
58
|
Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial.
|
Hepatology
|
2012
|
1.12
|
|
59
|
Antibody-mediated pure red cell aplasia due to epoetin alfa during antiviral therapy of chronic hepatitis C.
|
Am J Gastroenterol
|
2005
|
1.09
|
|
60
|
Liver and intestine transplantation: summary analysis, 1994-2003.
|
Am J Transplant
|
2005
|
1.09
|
|
61
|
Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial.
|
Hepatology
|
2009
|
1.08
|
|
62
|
Treatment of chronic hepatitis C virus in the virginia department of corrections: can compliance overcome racial differences to response?
|
Am J Gastroenterol
|
2004
|
1.08
|
|
63
|
Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.
|
Gastroenterology
|
2011
|
1.07
|
|
64
|
An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C.
|
PLoS One
|
2011
|
1.04
|
|
65
|
R1626 plus peginterferon Alfa-2a provides potent suppression of hepatitis C virus RNA and significant antiviral synergy in combination with ribavirin.
|
Hepatology
|
2008
|
1.03
|
|
66
|
Strategies for managing anemia in hepatitis C patients undergoing antiviral therapy.
|
Am J Gastroenterol
|
2007
|
1.03
|
|
67
|
Induction pegylated interferon alfa-2a and high dose ribavirin do not increase SVR in heavy patients with HCV genotype 1 and high viral loads.
|
Gastroenterology
|
2010
|
1.00
|
|
68
|
A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation.
|
Liver Transpl
|
2007
|
0.99
|
|
69
|
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection.
|
Hepatology
|
2014
|
0.98
|
|
70
|
Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C.
|
Clin Gastroenterol Hepatol
|
2008
|
0.98
|
|
71
|
Excess mortality in patients with advanced chronic hepatitis C treated with long-term peginterferon.
|
Hepatology
|
2011
|
0.98
|
|
72
|
Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival.
|
Transplantation
|
2007
|
0.97
|
|
73
|
Efficacy and safety of two-dose regimens of peginterferon alpha-2a compared with interferon alpha-2a in chronic hepatitis C: a multicenter, randomized controlled trial.
|
Am J Gastroenterol
|
2004
|
0.95
|
|
74
|
Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.
|
J Gastroenterol Hepatol
|
2006
|
0.94
|
|
75
|
A phase III study of the safety and efficacy of viramidine versus ribavirin in treatment-naïve patients with chronic hepatitis C: ViSER1 results.
|
Hepatology
|
2009
|
0.93
|
|
76
|
Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation.
|
Liver Int
|
2012
|
0.92
|
|
77
|
Steatohepatitis: Risk factors and impact on disease severity in human immunodeficiency virus/hepatitis C virus coinfection.
|
Hepatology
|
2008
|
0.92
|
|
78
|
Interpretation of positive transcription-mediated amplification test results from polymerase chain reaction-negative samples obtained after treatment of chronic hepatitis C.
|
Hepatology
|
2008
|
0.91
|
|
79
|
Similar progression of fibrosis between HIV/HCV-infected and HCV-infected patients: Analysis of paired liver biopsy samples.
|
Clin Gastroenterol Hepatol
|
2010
|
0.90
|
|
80
|
Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation.
|
Liver Transpl
|
2004
|
0.90
|
|
81
|
Benign recurrent intrahepatic cholestasis.
|
Clin Liver Dis
|
2004
|
0.89
|
|
82
|
Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response.
|
Clin Liver Dis
|
2005
|
0.88
|
|
83
|
A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis.
|
Clin Gastroenterol Hepatol
|
2008
|
0.87
|
|
84
|
Incidence of prolonged length of stay after orthotopic liver transplantation and its influence on outcomes.
|
Liver Transpl
|
2009
|
0.87
|
|
85
|
Comparison of performance characteristics of three real-time reverse transcription-PCR test systems for detection and quantification of hepatitis C virus.
|
J Clin Microbiol
|
2007
|
0.87
|
|
86
|
Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
|
Clin Transplant
|
2004
|
0.85
|
|
87
|
Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection.
|
Clin Gastroenterol Hepatol
|
2004
|
0.85
|
|
88
|
Use of diagnostic testing for managing hepatitis C virus infection.
|
Semin Liver Dis
|
2004
|
0.85
|
|
89
|
Response to hepatitis A and B vaccine alone or in combination in patients with chronic hepatitis C virus and advanced fibrosis.
|
Dig Dis Sci
|
2009
|
0.85
|
|
90
|
Herpes simplex virus colitis in a patient with Crohn's disease and hepatitis B and d cirrhosis.
|
Gastroenterol Hepatol (N Y)
|
2010
|
0.84
|
|
91
|
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C.
|
J Hepatol
|
2003
|
0.83
|
|
92
|
Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels.
|
J Clin Gastroenterol
|
2010
|
0.83
|
|
93
|
Sofosbuvir Plus Velpatasvir Combination Therapy for Treatment-Experienced Patients With Genotype 1 or 3 Hepatitis C Virus Infection: A Randomized Trial.
|
Ann Intern Med
|
2015
|
0.83
|
|
94
|
Approach to the management of patients with chronic hepatitis C who failed to achieve sustained virologic response.
|
Infect Dis Clin North Am
|
2006
|
0.82
|
|
95
|
Controversies in the management of hepatitis C patients with advanced fibrosis and cirrhosis.
|
Clin Gastroenterol Hepatol
|
2004
|
0.82
|
|
96
|
High relapse rate seen at week 72 for patients treated with R1626 combination therapy.
|
Hepatology
|
2008
|
0.82
|
|
97
|
Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response.
|
Antivir Ther
|
2009
|
0.82
|
|
98
|
Calcineurin inhibitor-induced chronic nephrotoxicity in liver transplant patients is reversible using rapamycin as the primary immunosuppressive agent.
|
Clin Transplant
|
2002
|
0.82
|
|
99
|
The spectrum of chronic hepatitis C virus infection in the Virginia Correctional System: development of a strategy for the evaluation and treatment of inmates with HCV.
|
Am J Gastroenterol
|
2005
|
0.81
|
|
100
|
Prophylaxsis against recurrance of hepatitis B virus after liver transplantation: a retrospective analysis spanning 20 years.
|
Liver Int
|
2007
|
0.81
|
|
101
|
Mild alcohol consumption is not associated with increased fibrosis in patients with chronic hepatitis C.
|
J Clin Gastroenterol
|
2011
|
0.80
|
|
102
|
The role of interferon in the new era of hepatitis C treatments.
|
Expert Rev Gastroenterol Hepatol
|
2014
|
0.79
|
|
103
|
Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
|
Am J Gastroenterol
|
2012
|
0.78
|
|
104
|
Intensive interferon therapy does not increase virological response rates in African Americans with chronic hepatitis C.
|
Dig Dis Sci
|
2003
|
0.78
|
|
105
|
The clinical spectrum of hepatitis C virus in HIV coinfection.
|
J Acquir Immune Defic Syndr
|
2003
|
0.78
|
|
106
|
A randomized, double-blind, placebo-controlled dose-escalation trial of merimepodib (VX-497) and interferon-alpha in previously untreated patients with chronic hepatitis C.
|
Antivir Ther
|
2005
|
0.78
|
|
107
|
In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions.
|
Liver Int
|
2013
|
0.77
|
|
108
|
The systemic safety of bromfenac ophthalmic solution 0.09%.
|
J Ocul Pharmacol Ther
|
2007
|
0.76
|
|
109
|
Impact of the donor liver with steatosis in patients with hepatitis C virus: not so FAst.
|
Liver Transpl
|
2009
|
0.76
|
|
110
|
The practical management of treatment failure in chronic hepatitis C: a summary of current research and management options for refractory patients.
|
Gastroenterol Hepatol (N Y)
|
2007
|
0.75
|
|
111
|
Use of ribavirin in patients with chronic HCV genotype 1: when enough is really enough.
|
Gastroenterology
|
2006
|
0.75
|
|
112
|
Living donor liver transplantation in patients with chronic hepatitis C: timing is everything.
|
Liver Transpl
|
2003
|
0.75
|
|
113
|
Treating chronic hepatitis C virus after liver transplantation: balancing the risks against the chance for success.
|
Liver Transpl
|
2007
|
0.75
|
|
114
|
Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study.
|
Clin Infect Dis
|
2014
|
0.75
|
|
115
|
Intensified peginterferon α-2a dosing increases sustained virologic response rates in heavy, high viral load hepatitis C genotype 1 patients with high low-density lipoprotein.
|
J Clin Gastroenterol
|
2013
|
0.75
|
|
116
|
Corrigendum: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
|
Am J Gastroenterol
|
2016
|
0.75
|